RG
SLRN

Redmile Group’s ACELYRIN SLRN Stock Holding History

Redmile Group’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-364,493
Closed -$7.62M – 74
2023
Q2 		$7.62M Buy
+364,493
New +$7.45M 0.29% 53

Other funds holding SLRN

ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $426M AUM 838% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Redmile Group's SLRN Position: Q3 2023 in Review

Redmile Group sold out of ACELYRIN (SLRN) in Q3 2023, closing a stake of 364,493 shares — an estimated $7.62M sold.

Redmile Group first reported a position in SLRN in Q2 2023 and held it in 1 quarter. The position peaked at $7.62M in Q2 2023. 101 funds tracked by Wall St. Rank hold SLRN as of Q3 2023.

  • Redmile Group reported no remaining ACELYRIN position as of Q3 2023 after selling out during the quarter.
  • Redmile Group sold 364,493 ACELYRIN shares in Q3 2023, an estimated $7.62M.
  • Redmile Group first reported a position in ACELYRIN in Q2 2023 and held it in 1 quarter.
  • Redmile Group's ACELYRIN position peaked at $7.62M in Q2 2023.
  • 101 funds tracked by Wall St. Rank held ACELYRIN as of Q3 2023.

Based on Redmile Group's 13F filing for Q3 2023, filed 14 Nov 2023.